论文部分内容阅读
背景与目的长春瑞滨+顺铂/卡铂(NP)方案是晚期非小细胞肺癌(NSCLC)患者的标准化疗方案之一。本课题通过研究NSCLC患者肿瘤组织中3型β微管蛋白(β-tubulin-Ⅲ)和Stathmin蛋白的表达与患者对NP方案敏感性的关系,为个体化治疗方案的制定提供择药依据。方法以Western blot法测定患者肿瘤组织中β-tubulin-Ⅲ和Stathmin蛋白的表达,依据表达高低分为4组:二者均低表达的L组,仅β-tubulin-Ⅲ低表达的B组,仅Stathmin低表达的S组,及二者皆高表达的H组;同时所有患者接受2或4周期的长春瑞滨+顺铂/卡铂(NP)方案化疗,观察各组患者的有效率(response rate,RR)、中位生存期(media survival time,MST)、疾病进展时间(timetoprogress,TTP)。结果共90例ⅢB-Ⅳ期的NSCLC患者入组,L组22例,B组、S组均23例,H组22例,各组RR分别为68.2%、26.1%、30.4%、22.7%,L组优于其它3组(P<0.05);各组MST分别为377天、305天、321天、271天,TTP分别为240天、182天、190天、166天,均显示出L组优于其它3组(P<0.05)。结论NSCLC患者肿瘤组织中β-tubulin-Ⅲ和Stathmin蛋白的表达,与患者对NP方案的敏感性有关,可作为选择合适化疗药物的参考。
Background and objective Vinorelbine + cisplatin / carboplatin (NP) regimen is one of the standard chemotherapy regimens in patients with advanced non-small cell lung cancer (NSCLC). In this study, we investigated the relationship between the expression ofβ-tubulin-Ⅲ and Stathmin in NSCLC patients and the sensitivity of NP regimen in patients with NSCLC, and provided evidence for the development of individualized treatment regimens. Methods The expressions of β-tubulin-Ⅲ and Stathmin in tumor tissue were determined by Western blot. According to the expression of β-tubulin-Ⅲ and Stathmin, the expression of β-tubulin-Ⅲ and Stathmin were divided into four groups: Only Stathmin low expression of the S group, and both high expression of H group; all patients undergoing 2 or 4 cycles of vinorelbine + cisplatin / carboplatin (NP) regimen chemotherapy to observe the efficacy of each group of patients ( response rate (RR), media survival time (MST), and time to progress (TTP). Results A total of 90 patients with stage ⅢB-Ⅳ NSCLC were enrolled in this study. There were 22 cases in group L, 23 cases in group B, 23 cases in group S and 22 cases in group H, with RR of 68.2%, 26.1%, 30.4% and 22.7% L group was superior to the other three groups (P <0.05). The MST of each group was 377 days, 305 days, 321 days and 271 days, respectively. The TTP was 240 days, 182 days, 190 days and 166 days respectively. Better than the other three groups (P <0.05). Conclusion The expression of β-tubulin-Ⅲ and Stathmin in tumor tissue of patients with NSCLC is related to the sensitivity of patients to NP regimen and can be used as a reference for selecting suitable chemotherapeutic drugs.